US spending exceeds $10 billion: https://time.com/5921360/operation-warp-speed-vaccine-spending/ https://time.com/5921360/operation-warp-speed-vaccine-spendi...

US spending exceeds $10 billion: https://time.com/5921360/operation-warp-speed-vaccine-spending/ https://time.com/5921360/operation-warp-speed-vaccine-spendi... (the Biden administration has since committed further funds also) That NPR article proceeds on the very unlikely assumption that unused vaccines will not be reallocated to other countries. It's also hard to really judge the potential other scenarios in the overall situation; the US production ramp up is going to benefit everyone in the medium term, and it's not really clear that it would have been much different if BioNTech partnered with a different manufacturer (much of the work in the US is being done at purpose built contract manufacturer facilities; AstraZenaca and J&J share some sites...). Edit: There's also the question of whether potential partners were really interchangeable, or if Pfizer has some advantage in knowledge or whatever.